Sean V. Tavtigian, PhD
Professor, Oncological Sciences, Huntsman Cancer Institute, University of Utah

Dr Tavtigian received a BA in biology and chemistry from Pomona college in 1984 and then a PhD in molecular biology and biochemistry from the California Institute of Technology in 1992. From 1993 until 2002, he worked at Myriad Genetics, contributing to the characterization of CDKN2A, BRCA1, BRCA2, and PTEN genes. In late 2002, he moved to the WHO International Agency for Research on Cancer (IARC) where he headed the Genetic Cancer Susceptibility Group. While there, he developed one of the leading models for in silico analysis of missense substitutions, contributed to an international effort to develop a method for evaluating unclassified variants in BRCA1 and BRCA2, and helped develop a clinical guideline for translating those results to patient care. In 2009, he moved to the University of Utah’s Huntsman Cancer Institute where he is now co-leader of the Cancer Control and Population Sciences Program. His current interests include (i) analysis of unclassified sequence variants observed during clinical testing of high-risk cancer susceptibility genes, (ii) case-control mutation screening of candidate intermediate-risk breast cancer susceptibility genes, and (iii) massively parallel sequencing-driven cancer susceptibility gene discovery efforts.